HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Weighs Options For OTC Division As Investors Line Up For Purchase

This article was originally published in The Rose Sheet

Executive Summary

While Pfizer considers whether to sell its Consumer Healthcare unit or spin it off to shareholders, potential buyers are placing bids with an eye toward an early June deadline

You may also be interested in...



Colgate on acquisitions

Colgate-Palmolive would "not easily move into" OTC or pharmaceutical categories, CEO Reuben Mark states during June 1 Sanford Bernstein Strategic Decisions Conference. Colgate has been identified as a potential bidder for Pfizer's Consumer Healthcare unit, which in addition to OTCs includes the Listerine oral care brand (1"The Rose Sheet" May 29, 2006, p. 4). Pfizer has expressed it is not interested in selling its brands individually. Separately, Mark notes the firm's advertising spend will be up a record 13%-14% in 2006. Colgate spent $297.1 mil. behind its global brands in the first quarter (2"The Rose Sheet" March 14, 2006, p. 4). The company also placed a record amount behind advertising last year, with spending up 11.5%, exec notes...

Colgate on acquisitions

Colgate-Palmolive would "not easily move into" OTC or pharmaceutical categories, CEO Reuben Mark states during June 1 Sanford Bernstein Strategic Decisions Conference. Colgate has been identified as a potential bidder for Pfizer's Consumer Healthcare unit, which in addition to OTCs includes the Listerine oral care brand (1"The Rose Sheet" May 29, 2006, p. 4). Pfizer has expressed it is not interested in selling its brands individually. Separately, Mark notes the firm's advertising spend will be up a record 13%-14% in 2006. Colgate spent $297.1 mil. behind its global brands in the first quarter (2"The Rose Sheet" March 14, 2006, p. 4). The company also placed a record amount behind advertising last year, with spending up 11.5%, exec notes...

Colgate Snaps Up Tom’s Of Maine In $100 Mil. Deal

Colgate-Palmolive's planned acquisition of natural toothpaste marketer Tom's of Maine will establish the company as the only global oral care firm that serves the health and specialty trade channel, Colgate announced March 21

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013970

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel